HBRCA84D CAR-T (Ucl Cancer Trials Centre)

N/A

Report date: 2026/04/27 20:02:09

Base Information

Drug NameHBRCA84D CAR-T (Ucl Cancer Trials Centre)

Drug Alias NameAutologous hBRCA84D CAR-T cells (Ucl Cancer Trials Centre)hBRCA84D CAR T (Ucl Cancer Trials Centre)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Source of cells > Peripheral blood-derived

Mechanisms of ActionAnti-CD276

TargetsCD276 antigen

Therapy Area/IndicationsDesmoplastic Small Round Cell TumorRhabdomyosarcomaSarcoma, Ewing

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited Kingdom

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesUcl Cancer Trials Centre

China Registration ClassN/A

Develop Information

Active CompaniesUcl Cancer Trials Centre

Inactive CompaniesN/A

Active IndicationsDesmoplastic Small Round Cell TumorRhabdomyosarcomaSarcoma, Ewing

Inactive IndicationsN/A

Other Information

ATC CodeN/A